FDA Approves Regeneron Rare Bone Drug
The US FDA approved Regenerons Pasatru for a rare genetic disorder causing abnormal bone formation in soft tissues. In trials, the treatment reduced new bone abnormalities significantly compared to a placebo. Shares of Regeneron rose following the announcement.
Xurve View
Insights:
Xurve View
REGENERON PHARMACEUTICALS secured United States approval for its rare bone disorder drug, cutting abnormal bone formation by up to 94%. Shares of the drugmaker rose 4% following the regulatory decision.
